Company Search:
Advanced Search
Sponsored Links
Genmab A/S - ADR Company Snapshot
Genmab A/S operates in the Commercial physical research sector. In addition to historical fundamental analyses, the complete report available to purchase compares Genmab A/S with three other companies in this sector in UNITED STATES : Exelixis, Inc. (2019 sales of $967.78 million of which 100% was Oncology focused biotechnology), Medpace Holdings Inc ($860.97 million of which 100% was SERVICES-COMMERCIAL PHYSICAL & BIOLOGICA), and Exact Sciences Corporation ($876.29 million of which 100% was License fees).

Sales Analysis. Genmab A/S reported sales of $803.40 million for the year ending December of 2019. This represents an increase of 68.0% versus 2018, when the company's sales were $478.18 million. Sales at Genmab A/S have increased during each of the previous five years (and since 2014, sales have increased a total of 433%).
  Stock Performance Chart for Genmab A/S - ADR
  Stock Data: Recent Stock Performance:
  Current Price (9/25/2020): 36.02
(Figures in U.S. Dollars)
1 Week -6.9%   13 Weeks -3.2%  
4 Weeks 12.6%   52 Weeks 82.2%  
Genmab A/S - ADR Key Data:
  Ticker: GMAB Country: United States
  Exchanges: OTC Major Industry: Commercial Services & Supplies
    Sub Industry: Commercial Physical Research
  2019 Sales 803,397,520
(Year Ending Jan 2020).
Employees: 548
  Currency: U.S. Dollars Market Cap: 23,488,623,990
  Fiscal Yr Ends: December Shares Outstanding: 652,099,500
  Share Type: Common Closely Held Shares: 30,379,340
Feedback | Terms and Conditions | Privacy Policy | Site Index
CorporateInformation® website and selected data Copyright © 2000 - by The Winthrop Corporation. All Rights Reserved. Except for quotations by established news media, no pages on this site may be reproduced, stored in a retrieval system, or transmitted for commercial purposes, in any form or by any means, electronic, mechanical, photocopying, recording, or otherwise without prior written permission. Information is believed reliable, but accuracy, completeness and opinions are not guaranteed.